Publications

  1. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Jun 06. [Epub ahead of print] 2328459
    View PubMed
  2. Lasho T, Johnson SH, Smith DI, Crispino JD, Pardanani A, Vasmatzis G, Tefferi A. Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. Am J Hematol. 2013 Jun 03. [Epub ahead of print] 2327433
    View PubMed
  3. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun; 27(6):1322-7. Epub 2013 Mar 05. 2313613
    View PubMed
  4. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2013 Jun; 54(6):1263-7. Epub 2012 Nov 19. 2310421
    View PubMed
  5. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Hanson CA, Tefferi A. Increased circulating IL-2Ralpha (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study. Leukemia. 2013 Jun; 27(6):1430-3. Epub 2013 Jan 15. 2296272
    View PubMed
  6. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013 May 30. [Epub ahead of print] 2326531
    View PubMed
  7. Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol. 2013 May 20. [Epub ahead of print] 2324731
    View PubMed
  8. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013 Apr 22. [Epub ahead of print] 2318505
    View PubMed
  9. Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood. 2013 Apr 18; 121(16):3085-94. Epub 2013 Feb 20. 2305461
    View PubMed
  10. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia. 2013 Apr 05. [Epub ahead of print] 2315033
    View PubMed
  11. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013 Apr; 88(4):312-6. Epub 2013 Feb 28. 2307583
    View PubMed
  12. Patnaik MM, Padron E, Laborde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-Kali A, Pardanani A, Ali NA, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Mar 27. [Epub ahead of print] 2313185
    View PubMed
  13. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013 Mar; 88(3):201-6. Epub 2013 Jan 18. 2297906
    View PubMed
  14. Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013 Feb 1; 73(3):1076-85. Epub 2012 Oct 11. 2292398
    View PubMed
  15. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012 Nov 15; 120(20):4168-71. Epub 2012 Sep 11. 2269959
    View PubMed
  16. D'Souza A, Pardanani A, Tefferi A. Lymphoma-associated versus lymphocytic-variant hypereosinophilia. Leuk Lymphoma. 2012 Nov; 53(11):2103-4. Epub 2012 Aug 13. 2263956
    View PubMed
  17. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, Tefferi A. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012 Nov; 87(11):1003-5. Epub 2012 Sep 11. 2269951
    View PubMed
  18. Pardanani A. Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1117-28. 2272782
    View PubMed
  19. Hussain FT, Nguyen EP, Raza S, Knudson R, Pardanani A, Hanson CA, Van Dyke D, Tefferi A. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Am J Hematol. 2012 Jul; 87(7):684-6. Epub 2012 May 06. 2243851
    View PubMed
  20. Bleeker JS, Syed FF, Cooper LT, Weiler CR, Tefferi A, Pardanani A. Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. Am J Hematol. 2012 Jul; 87(7):703-6. Epub 2012 Feb 24. 2227598
    View PubMed
  21. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. Epub 2012 Mar 28. 2242607
    View PubMed
  22. Pardanani A, Lasho TL, Finke CM, Rajkumar SV, Singh PP, Ketterling RP, Hanson CA, Katzmann JA, Tefferi A. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012 Apr 1; 30(10):1087-94. Epub 2012 Feb 13. 2224245
    View PubMed
  23. Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol. 2012 Apr; 87(4):401-11. 2235358
    View PubMed
  24. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, Tefferi A. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012 Apr; 26(4):693-9. Epub 2011 Sep 13. 2190701
    View PubMed
  25. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol. 2012 Mar; 88(3):237-43. Epub 2011 Nov 17. 2201833
    View PubMed
  26. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, McClure RF, Pardanani A. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012 Mar; 26(3):475-80. Epub 2011 Sep 13. 2190674
    View PubMed
  27. Raza S, Viswanatha D, Frederick L, Lasho T, Finke C, Knudson R, Ketterling R, Pardanani A, Tefferi A. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012 Feb; 87(2):204-6. Epub 2011 Nov 4. 2203477
    View PubMed
  28. Vaa BE, Wolanskyj AP, Roeker L, Pardanani A, Lasho TL, Finke CM, Tefferi A. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol. 2012 Feb; 87(2):136-8. Epub 2011 Nov 12. 2206653
    View PubMed
  29. Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva H, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb; 26(2):280-8. Epub 2011 Oct 21. 2228623
    View PubMed
  30. Syed FF, Bleeker JS, Glockner J, Pardanani A, Cooper LT Jr. Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging. J Am Coll Cardiol. 2012 Jan 24; 59(4):430. 2219786
    View PubMed
  31. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119(2):569-72. Epub 2011 Nov 17. 2206625
    View PubMed
  32. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012 Jan; 87(1):66-8. Epub 2011 Nov 12. 2206598
    View PubMed
  33. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012 Jan; 26(1):101-5. Epub 2011 Oct 28. 2201893
    View PubMed
  34. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan; 87(1):25-33. 2215161
    View PubMed
  35. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011 Dec; 86(12):1188-91. Epub 2011 Oct 27. 2201959
    View PubMed
  36. Pardanani A, Drake MT, Finke C, Lasho TL, Rozell SA, Jimma T, Tefferi A. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Am J Hematol. 2011 Dec; 86(12):1013-6. 2206594
    View PubMed
  37. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011 Dec; 25(12):1834-9. Epub 2011 Jun 21. 2172212
    View PubMed
  38. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1; 117(21):4869-77. Epub 2011 Apr 08. 2157487
    View PubMed
  39. Pardanani A. JAK2 inhibitors in myelofibrosis. Clin Adv Hematol Oncol. 2011 Nov; 9(11):856-8. 2218080
    View PubMed
  40. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Pardanani A. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood. 2011 Oct 27; 118(17):4595-8. Epub 2011 Aug 31. 2187823
    View PubMed
  41. Smith JH, Butterfield JH, Pardanani A, DeLuca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg. 2011 Sep; 113(7):570-4. Epub 2011 Jun 12. 2170035
    View PubMed
  42. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011 Sep; 25(5):229-37. Epub 2011 Jul 13. 2196878
    View PubMed
  43. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011 Aug; 86(8):701-2. Epub 2011 Jun 14. 2170017
    View PubMed
  44. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A, Pardanani A, Lin FT, Li J, Sha B, Benveniste EN. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood. 2011 Jul 7; 118(1):156-66. Epub 2011 Apr 28. 2179674
    View PubMed
  45. Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, Pardanani A, Tefferi A. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011 May 26; 117(21):5612-5. Epub 2011 Mar 30. 2155568
    View PubMed
  46. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011 Apr 1; 29(10):1356-63. Epub 2011 Feb 07. 2147407
    View PubMed
  47. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011 Apr; 86(4):362-71. 2155674
    View PubMed
  48. Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011 Apr; 96(4):590-601. Epub 2011 Jan 17. 2164100
    View PubMed
  49. Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011 Apr; 86(4):343-5. 2155616
    View PubMed
  50. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 1; 29(7):789-96. Epub 2011 Jan 10. 2141448
    View PubMed
  51. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal. 2011 Mar; 1:e7. 2221715
  52. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011 Mar; 18(2):105-10. 2143374
    View PubMed
  53. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20; 29(6):761-70. Epub 2011 Jan 04. 2157365
    View PubMed
  54. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1; 29(4):392-7. Epub 2010 Dec 13. 2160181
    View PubMed
  55. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011 Feb; 25(2):218-25. Epub 2010 Nov 16. 2124022
    View PubMed
  56. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb; 25(2):301-4. Epub 2010 Nov 05. 2124068
    View PubMed
  57. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011 Jan; 25(1):82-8. Epub 2010 Oct 14. 2204956
    View PubMed
  58. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011 Jan; 86(1):96-8. 2129384
    View PubMed
  59. Pardanani A. Advances in LLM: JAK2 Inhibitors in myelofibrosis. Clin. adv. hematol. oncol. 2011; 9(11):856-8. 2211606
  60. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010 Oct; 24(10):1713-8. Epub 2010 Aug 19. 2111514
    View PubMed
  61. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010 Oct; 95(10):1788-91. 2118491
    View PubMed
  62. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. 2114798
    View PubMed
  63. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010 Sep; 85(9):675-86. 2115547
    View PubMed
  64. Pardanani A, Tefferi A. Response criteria in systemic mastocytosis: moving forward with practical assessment that reflects meaningful health outcome. Eur J Haematol. 2010 Jul; 85(1):90 Epub 2010 Apr 28. 2106753
    View PubMed
  65. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010 Jul; 24(7):1283-9. Epub 2010 May 20. 2002117
    View PubMed
  66. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Jul; 24(7):1302-9. Epub 2010 May 27. 2002041
    View PubMed
  67. Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol. 2010 Jun; 84(6):518-24. Epub 2010 Mar 11. 1992826
    View PubMed
  68. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010 Jun; 24(6):1146-51. Epub 2010 Apr 22. 1997820
    View PubMed
  69. Lakey MA, Pardanani A, Hoyer JD, Nguyen PL, Lasho TL, Tefferi A, Hanson CA. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol. 2010 Jun; 133(6):942-8. 2002153
    View PubMed
  70. Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010 May; 84(5):371-8. Epub 2010 Jan 05. 1986067
    View PubMed
  71. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010 Apr; 85(4):238-42. 1985042
    View PubMed
  72. Tefferi A, Pardanani A. Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. Leuk Lymphoma. 2010 Mar; 51(3):360-2. 1985057
    View PubMed
  73. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol. 2010 Mar; 84(3):191-200. Epub 2009 Nov 30. 1988114
    View PubMed
  74. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010 Mar; 17(2):125-32. 1982543
    View PubMed
  75. Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010 Mar; 85(3):171-3. 1980537
    View PubMed
  76. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010 Feb 1; 84(2):105-8. Epub 2009 Nov 06. 1971350
    View PubMed
  77. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010 Feb; 85(2):158-64. Epub 2010 Jan 06. 1980531
    View PubMed
  78. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010 Jan 21; 115(3):496-9. Epub 2009 Nov 09. 1971318
    View PubMed
  79. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010 Jan; 24(1):105-9. Epub 2009 Oct 22. 1969658
    View PubMed
  80. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010 Jan; 24(1):110-4. Epub 2009 Oct 22. 1969659
    View PubMed
  81. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010 Jan; 85(1):14-7. 1978278
    View PubMed
  82. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec; 84(12):790-4. 1971358
    View PubMed
  83. Vaidya R, Siragusa S, Huang J, Schwager SM, Hanson CA, Hussein K, Pardanani A, Tefferi A. Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc. 2009 Dec; 84(12):1114-9. 1975563
    View PubMed
  84. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009 Oct 29; 114(18):3769-72. Epub 2009 Aug 27. 1959586
    View PubMed
  85. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203. Epub 2009 Feb 27. 1928099
    View PubMed
  86. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009 Aug; 23(8):1441-5. Epub 2009 Mar 19. 1933734
    View PubMed
  87. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009 Jun 4; 113(23):5727-36. Epub 2009 Apr 10. 1937457
    View PubMed
  88. Fink SR, Belongie KJ, Paternoster SF, Smoley SA, Pardanani AD, Tefferi A, Van Dyke DL, Ketterling RP. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res. 2009 Jun; 33(6):843-6. Epub 2008 Dec 31. 2106780
    View PubMed
  89. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23(5):905-11. Epub 2009 Mar 05. 1929748
    View PubMed
  90. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 May; 23(5):900-4. Epub 2009 Mar 05. 1929749
    View PubMed
  91. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84(5):265-7. 1938365
    View PubMed
  92. Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J, Bale S, Compton J, LeDuc CA, Pardanani A, Thorland EC, Shevchenko Y, Grodman M, Chung WK. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res. 2009 May; 33(5):662-4. Epub 2008 Oct 19. 1915501
    View PubMed
  93. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009 Apr; 82(4):255-9. Epub 2008 Feb 10. 1923912
    View PubMed
  94. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008 Jul; 22(7):1299-307. Epub 2008 May 22. 1909479
    View PubMed
  95. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15. 1909425
    View PubMed
  96. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008 Jun 15; 112(12):2726-32. 1885211
    View PubMed
  97. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol. 2008 Jun; 83(6):451-3. 1888373
    View PubMed
  98. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008 May; 83(5):363-5. 1883204
    View PubMed
  99. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol. 2008 May; 80(5):386-90. Epub 2008 Jan 23. 1874208
    View PubMed
  100. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008 Apr; 83(4):457-9. 1872057
    View PubMed
  101. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008 Apr; 22(4):756-61. Epub 2008 Jan 24. 1883034
    View PubMed
  102. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008 Mar 1; 111(5):2785-9. Epub 2007 Nov 15. 1872154
    View PubMed
  103. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY, Ketterling RP, Tefferi A. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2008 Mar; 80(3):197-200. Epub 2007 Dec 07. 1867470
    View PubMed
  104. Pardanani A, Tefferi A. Primary eosinophilic disorders: a concise review. Curr Hematol Malig Rep. 2008 Jan; 3(1):37-43. 1997901
    View PubMed
  105. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008 Jan; 22(1):23-30. Epub 2007 Sep 20. 1867452
    View PubMed
  106. Lim KH, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol. 2008; 119(4):194-8. Epub 2008 Jun 20. 1892676
    View PubMed
  107. Pardanani A, Verstovsek S. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. Cancer J. 2007 Nov-Dec; 13(6):384-91. 1867207
    View PubMed
  108. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007 Sep; 7(9):673-83. 1841522
    View PubMed
  109. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007 Sep; 25(9):2358-62. Epub 2007 May 31. 1841493
    View PubMed
  110. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007 Sep; 21(9):1960-3. Epub 2007 Jun 28. 1841417
    View PubMed
  111. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21. 1841418
    View PubMed
  112. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug; 21(8):1658-68. Epub 2007 May 31. 1837050
    View PubMed
  113. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007 Aug; 21(8):1827-8. Epub 2007 Apr 26. 1837051
    View PubMed
  114. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007 Aug; 138(3):354-8. 1834762
    View PubMed
  115. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007 Jun 1; 109(11):2279-84. 1827876
    View PubMed
  116. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007 May 15; 109(10):2083-8. 1822382
    View PubMed
  117. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res. 2007 May; 31(5):691-4. Epub 2006 Nov 13. 1822509
    View PubMed
  118. Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc. 2007 May; 82(5):599-604. 1824601
    View PubMed
  119. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007 May; 131(5):784-91. 1827958
    View PubMed
  120. Patnaik MM, Tefferi A, Pardanani A. Kit: Molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets. 2007; 7(5):492-503. 1975810
    View PubMed
  121. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006 Dec; 135(5):683-7. 1791355
    View PubMed
  122. Pardanani A. Dysregulated EVI1 expression in myeloid malignancies. Leuk Lymphoma. 2006 Dec; 47(12):2443-4. 1799602
    View PubMed
  123. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica. 2006 Dec; 91(12 Suppl):ECR57. 1853465
    View PubMed
  124. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10):3472-6. Epub 2006 Jul 25. 1792903
    View PubMed
  125. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006 Aug; 30(8):965-70. Epub 2006 Jan 06. 1770129
    View PubMed
  126. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun; 133(5):468-92. 1760779
    View PubMed
  127. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res. 2006 Jun; 30(6):739-44. Epub 2006 Feb 07. 1760822
    View PubMed
  128. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc. 2006 Apr; 81(4):553-63. 1757049
    View PubMed
  129. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol. 2006; 19(3):595-615. 1770176
    View PubMed
  130. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol. 2005; 114(1):41-51. 1718811
    View PubMed
  131. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004 Nov 15; 104(10):3038-45. Epub 2004 Jul 29. 1674464
    View PubMed
  132. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004 Oct 1; 104(7):1931-9. Epub 2004 May 27. 1667505
    View PubMed
  133. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients. Leuk Res. 2004 Aug; 28(8):777-83. 1653047
    View PubMed
  134. Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol. 2004 Jun; 79(5):441-7. 1653106
    View PubMed
  135. Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Current Hematology Reports. 2004 May; 3(3):197-202. 1663537
    View PubMed
  136. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res. 2004 May; 28 Suppl 1:S47-52. 1652846
    View PubMed
  137. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004 Feb; 28(2):127-31. 1517947
    View PubMed
  138. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004 Jan; 11(1):58-64. 1653001
    View PubMed
  139. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004; 89(7):871-3. 1657424
    View PubMed
  140. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003 Nov 1; 102(9):3093-6. Epub 2003 Jul 03. 1422277
    View PubMed
  141. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003 Oct; 27(10):883-5. 1405624
    View PubMed
  142. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet. 2003 Aug 16; 362(9383):535-6. 1407448
    View PubMed
  143. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003 Aug; 27(8):739-42. 1396830
    View PubMed
  144. Pardanani AD, Morice WG, Hoyer JD, Tefferi A. Chronic basophilic leukemia: a distinct clinico-pathologic entity? Eur J Haematol. 2003 Jul; 71(1):18-22. 1396859
    View PubMed
  145. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1; 101(9):3391-7. Epub 2002 Dec 27. 1346777
    View PubMed
  146. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1; 101(7):2534-41. Epub 2002 Nov 27. 1328733
    View PubMed
  147. Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis. Mayo Clin Proc. 2003 Mar; 78(3):301-6. 1318962
    View PubMed
  148. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003 Feb 1; 101(3):827-30. 1318292
    View PubMed
  149. Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol. 2003 Feb; 120(4):691-4. 1318654
    View PubMed
  150. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: A combined retrospective and prospective study. Mayo Clin Proc. 2002 Nov; 77(11):1169-75. 1316956
    View PubMed
  151. Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Primer on medical genomics Part IV: Expression proteomics. Mayo Clin Proc. 2002 Nov; 77(11):1185-96. 1316959
    View PubMed
  152. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99(10):3854-6. 1315722
    View PubMed
  153. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4; 359(9317):1577-8. 1315547
    View PubMed
  154. Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Bone marrow angiogenesis in systemic mast cell disease. J Hematother Stem Cell Res. 2002 Feb; 11(1):139-46. 1008262
    View PubMed
  155. Baek JY, Tefferi A, Pardanani A, Li CY. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res. 2002 Jan; 26(1):83-90. 1008109
    View PubMed
  156. Pardanani A, Gambacurta A, Ascoli F, Royer WE Jr. Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin: Structural basis for altered allosteric activity. J Mol Biol. 1998; 284:729-9. 1755738
    View PubMed
  157. Pardanani A, Gibson QH, Colotti G Royer WE Jr. Mutation of residue Phe 97 to Leu disrupts the central pathway of cooperativity in Scapharca dimeric hemoglobin. J Biol Chem. 1997 May 16; 272(20):13171-9. 1755739
    View PubMed
  158. Royer WE Jr, Pardanani A, Gibson QH, Peterson ES, Friedman JM. Ordered water molecules as key allosteric mediators in a cooperative dimeric hemoglobin. Proc Natl Acad Sci U S A. 1996 Dec 10; 93(25):14526-31. 1755740
    View PubMed
  159. Summerford CM, Pardanani A, Betts AH, Poteete AR, Colotti G, Royer WE Jr. Bacterial expression of Scapharca dimeric hemoglobin: a simple model system for investigating protein cooperatively. Protein Eng. 1995 Jun; 8(6):593-9. 1755741
    View PubMed
  160. Salomon M, Adams S, Pardanani A, Vazquez S, Humphreys RE, Lew RA. Comparison of actual and random-positioning-model distributions of peptide scavenging and T cell-presented sites in antigenic proteins. Vaccine. 1993; 11(10):1067-73. 1755742
    View PubMed